




(86) Date de dépôt PCT/PCT Filing Date: 2006/12/18
(87) Date publication PCT/PCT Publication Date: 2007/07/19
(45) Date de délivrance/Issue Date: 2015/05/05
(85) Entrée phase nationale/National Entry: 2008/07/11
(86) N° demande PCT/PCT Application No.: EP 2006/012183
(87) N° publication PCT/PCT Publication No.: 2007/079915
(30) Priorité/Priority: 2006/01/13 (FR06/00347)

(51) Cl.Int./Int.Cl. *A61K 31/166* (2006.01),
A61K 47/02 (2006.01), *A61K 47/14* (2006.01),
A61K 47/38 (2006.01), *A61K 47/44* (2006.01)
(72) Inventeurs/Inventors:
MOINET, GERARD, FR;
CRAVO, DANIEL, FR
(73) Propriétaire/Owner:
POXEL SAS, FR
(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : UTILISATION DE DERIVES DE TRIAZINE POUR LA FABRICATION D'UN MEDICAMENT PRESENTANT UN
EFFET CICATRISANT OU ANGIOGENIQUE
(54) Title: USE OF TRIAZINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT HAVING A CICATRISING
OR ANGIOGENIC EFFECT



(57) Abrégé/Abstract:

The present patent application relates to the use of triazine derivatives as cicatrising or angiogenic agents, wherein the triazine is a molecule of formula (I).



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 July 2007 (19.07.2007)

PCT

(10) International Publication Number
WO 2007/079915 A3

(51) International Patent Classification:

A61K 31/166 (2006.01) A61K 47/14 (2006.01)
A61K 47/44 (2006.01) A61K 47/02 (2006.01)
A61K 47/38 (2006.01)

(21) International Application Number:

PCT/EP2006/012183

(22) International Filing Date:

18 December 2006 (18.12.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

06/00347 13 January 2006 (13.01.2006) FR

(71) Applicant (for all designated States except US): **MERCK PATENT GMBH** [DE/DE]; Frankfurter Str. 250, 64293 Darmstadt (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MOINET, Gérard** [FR/FR]; 15, Rue Lamartine, F-91400 Orsay (FR).
CRAVO, Daniel [FR/FR]; 123, Avenue Jules Ferry, F-78500 Sartrouville (FR).

(74) Common Representative: **MERCK PATENT GMBH**; Frankfurter Str. 250, 64293 Darmstadt (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

30 August 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF TRIAZINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT HAVING A CICATRISING OR ANGIOGENIC EFFECT



(57) Abstract: The present patent application relates to the use of triazine derivatives as cicatrising or angiogenic agents, wherein the triazine is a molecule of formula (I).

WO 2007/079915 A3

USE OF TRIAZINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT HAVING A CICATRISING OR ANGIOGENIC EFFECT

Field of the invention

5 The present invention relates in particular to the use of triazine derivatives or pharmaceutically acceptable salts thereof for the manufacture of a medicament having a cicatrising and/or angiogenic effect.

Technical background

10 The cicatrisation of wounds or related damage on different types of tissue generally depends on the proliferation of new epithelial, endothelial and connective tissue. It thus involves a series of co-ordinated cellular and molecular events. It may be retarded or modified by metabolic disruptions that accompany certain protracted diseases, such as venous insufficiency, arteritis, diabetes and
15 even certain therapies.

 Angiogenesis, the formation of new blood vessels from the pre-existing vascular network, is essential for the growth of any tissue. It takes place, inter alia, in damaged tissue during its cicatrisation. It is well known that disruption of angiogenesis is associated with the development of many diseases involving a
20 deregulation of vascularisation. Many bibliographical data show, for example, a close link between the appearance of ulcers and the inhibition of angiogenesis in the case of diabetics. Furthermore, it is well documented that the endothelial cells constituting the blood vessels of the peripheral circulation are one of the many targets of damage induced by hyperglycaemia (diabetic microangio-
25 pathy). The pharmaceutical market currently offers many topical preparations recommended for the cicatrisation of wounds. In point of fact, their action results from the complementary nature of the various products of which they are composed and which gives them, to a certain extent, their cicatrising property. They protect wounds from the surrounding medium by means of an antiseptic dress-
30 ing. They stimulate the development of vascularisation and regulate epidermisation. These topical forms consist mainly of a lipid mixture (lanolin, petroleum jelly, glycerol, etc.) to which are added acids (salicylic acid, benzoic acid or malic acid), minerals (zinc oxide or titanium oxide) or halides (starch iodide).

Certain preparations also contain collagen, fibrinogen, serum enzymatic proteolysate (supply of amino acids) or alternatively vitamins (vitamin A) or hormones (4-chlorotestosterone acetate).

A pomade also exists (Madecasin® tulgras from Laboratoires Syntex),
 5 the cicatrising action of which is provided by the addition of a mixture of three triterpenes extracted from roots of the plant *Centella asiatica* (TCEA).

These compounds exert their property by stimulating the biosynthesis of collagen and of glycosaminoglycans. However, these extracts may also give rise to contact allergies in patients.


10 It is known that one of the complications of diabetes lies in the appearance of skin complaints, such as ulcers (or even ulcerous necrotic angiodermatitis) or perforating dermatitis, which conventional medicaments used for the treatment of diabetes do not manage to control or treat.

15 Description of the invention

The hypoglycaemiant properties of and preparations derived from triazines of the formula (I) have previously been described in FR 2 804 113 and WO 01/ 55122.

Unexpectedly, the applicant has now demonstrated that these com-
 20 pounds, or pharmaceutically acceptable salts thereof, also have a cicatrising and/or angiogenic effect.

More particularly, the invention relates to the use of derivatives of the general formula (I) below:



(I)

25

in which:

R1, R2, R3 and R4 are independently chosen from the following groups:

-H,

30 -(C1-C20)alkyl optionally substituted by halogen, (C1-C5)alkyl, (C1-C5)-alkoxy or (C3-C8)cycloalkyl,

-(C2-C20)alkenyl optionally substituted by halogen, (C1-C5)alkyl or (C1-C5)alkoxy

-(C2-C20)alkynyl optionally substituted by halogen, (C1-C5)alkyl or (C1-C5)alkoxy

5 -(C3-C8)cycloalkyl optionally substituted by (C1-C5)alkyl or (C1-C5)-alkoxy

-hetero(C3-C8)cycloalkyl bearing one or more heteroatoms chosen from N, O and S and optionally substituted by (C1-C5)alkyl or (C1-C5)alkoxy

10 -(C6-C14)aryl(C1-C20)alkyl optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,

15 - (C6-C14)aryl optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,

20 -(C1-C13)heteroaryl bearing one or more heteroatoms chosen from N, O and S and optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,

25 R1 and R2, on the one hand, and R3 and R4, on the other hand, possibly forming with the nitrogen atom an n-membered ring (n between 3 and 8) optionally containing one or more heteroatoms chosen from N, O and S and possibly being substituted by one or more of the following groups: amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,

R5 and R6 are independently chosen from the following groups:

30 -H,

-(C1-C20)alkyl optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)-

aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,

-(C2-C20)alkenyl optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)-
5 aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,

-(C2-C20)alkynyl optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)-
aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,
10

-(C3-C8)cycloalkyl optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,

15 -hetero(C3-C8)cycloalkyl bearing one or more heteroatoms chosen from N, O and S and optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,

20 -(C6-C14)aryl optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,

-(C1-C13)heteroaryl bearing one or more heteroatoms chosen from N, O and S and optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,
25

-(C6-C14)aryl(C1-C5)alkyl optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,
30


- R5 and R6 possibly forming with the carbon atom to which they are attached an m-membered ring (m between 3 and 8) optionally containing one or more heteroatoms chosen from N, O and S and possibly being substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl, or possibly forming with the carbon atom with the carbon atom a C10-C30 polycyclic residue optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)-alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxethyl, R5 and R6 together also possibly representing the group=O or =S, the nitrogen atom of a heterocycloalkyl or heteroaryl group possibly being substituted by a (C1-C5)alkyl, (C3-C8)cycloalkyl, (C6-C14)aryl, (C6-C14)aryl, (C6-C14)aryl(C1-C5)alkyl or (C1-C6)acyl group,

and also the racemic forms, tautomers, enantiomers, diastereoisomers, epimers and mixtures thereof, and the pharmaceutically acceptable salts thereof,

for the preparation of a medicament having a cicatrising and/or angiogenic effect.

According to one aspect, the present invention relates to the use of triazine derivatives of the general formula (I) below:

5a



in which:

R1, R2, R3 and R4 are independently chosen from the following groups:

- H,
- (C1-C20)alkyl optionally substituted by halogen, (C1-C5)alkyl, (C1-C5)-alkoxy or (C3-C8)cycloalkyl,

R5 and R6 are independently chosen from the following groups:

- H,
- (C1-C20)alkyl optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)-aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,

or the racemic forms, tautomers, enantiomers, diastereoisomers, epimers and polymorphs, or any mixtures thereof, or a pharmaceutically acceptable salt thereof,

in the preparation of a medicament for promoting cicatrisation, wherein the medicament is in a pharmaceutical form for local use.

The term "m-membered ring formed by R5 and R6" in particular means a saturated ring, such as a cyclohexyl piperidyl or tetrahydropyranyl group.

5b

The term "polycyclic group formed by R5 and R6" means an optionally substituted carbon –based polycyclic group and in particular as steroid residue.

One particular group of compounds of the formula (I) is that in which R5 is hydrogen.

Another particular group of compounds of the formula (I) is that in which R5 and R6 form with the carbon atom to which they are attached an m-membered ring (m between 3 and 8) optionally containing one or more heteroatoms chosen from N, O and S and possibly being substituted by one or more of the following groups: (C1-C5)alkyl, amino, hydroxyl, (C1-C5) alkylamino, alkoxy-(C1-C5), (C1-C5)alkylthio, (C6-C14)aryl, (C6-C14)aryl(C1-C5)alkoxy,

or form with the carbon atom a C10-C30 polycyclic residue optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy,

(C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)-alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl.

Another particular group of compounds of the formula (I) is that in which R5 and R6 are independently chosen from the following groups:



- 5 -(C1-C20)alkyl groups optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl.











10 Preferably, R1, R2, R3 and R4 are independently chosen from H and (C1-C20)alkyl groups optionally substituted by halogen, (C1-C5)alkyl, (C1-C5)alkoxy or (C3-C8)cycloalkyl; more preferably, R1=R2=H and R3=R4=(C1-C20)alkyl optionally substituted by halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C3-C8)cycloalkyl or vice versa.











15 Preferably, R5 and R6 are independently chosen from H and (C1-C20)alkyl groups optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)-aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxy-methyl or carboxyethyl; more preferably, R5=H and R6=(C1-C20)alkyl optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-
20 C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl or vice versa.










A more particular group of compounds of the formula (I) is that in which R1 and R2 are a methyl group and R3 and R4 represent a hydrogen.











Compounds of the formula (I) that may especially be mentioned include:





	Formula	Salt
1		HCl
2		HCl

3		
4		HCl
5		Methane-sulfonate
6		
7		HCl
8		HCl
9		HCl
10		HCl
11		HCl
12		HCl

13		
14		Fumarate
15		HCl
16		HCl
17		HCl
18		HCl
19		HCl
20		Carbonate
21		Carbonate
22		HCl

23		HCl
24		HCl
25		HCl
26		HCl
27		HCl
28		HCl
29		Carbonate
30		Carbonate
31		HCl

32		Carbonate
33		HCl
34		para-Toluene-sulfonate
35		HCl
36		para-Toluene-sulfonate
37		para-Toluene-sulfonate
38		HCl
39		HCl
40		HCl
41		para-Toluene-sulfonate

42		HCl
43		HCl
44		HCl
45		para-Toluene-sulfonate

and more preferably the compound of Example 18.

According to yet another preferred embodiment, the invention relates more particularly to the use of compounds chosen from:

- 5 • 2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine hydrochloride
- (+)-2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine hydrochloride
- (-)-2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine
- 10 hydrochloride.

The compounds of the invention of the formula (I) as defined above, containing a sufficiently basic function, or both, may include the corresponding pharmaceutically acceptable salts of organic or mineral acids.

For the purposes of the present invention, the term "corresponding
15 pharmaceutically acceptable salts of organic or mineral acids" means any salt prepared from any non-toxic pharmaceutically acceptable organic or inorganic acid. Such acids include acetic acid, benzenesulfonic acid, benzoic acid, citric acid, carbonic acid, ethanesulfonic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, lactic acid, mandelic acid, malic acid,
20 maleic acid, methanesulfonic acid, mucic acid, nitric acid, panto-

11756-73

12

thenic acid, phosphoric acid, succinic acid, tartaric acid and para-toluenesulfonic acid. Hydrochloric acid is advantageously used.

The invention also relates to the chiral salts of the compounds of the formula (I) used for the separation of the racemates.

By way of example, the following chiral acids are used: (+)-D-di-O-benzoyltartaric acid, (-)-L-di-O-benzoyltartaric acid, (-)-L-di-O,O'-p-toluyyl-L-tartaric acid, (+)-D-di-O,O'-p-toluyyl-L-tartaric acid, (*R*)-(+)-malic acid, (*S*)-(-)-malic acid, (+)-camphanic acid, (-)-camphanic acid, *R*-(-)-1,1'-binaphthalen-2,2'-diylhydrogenophosphonic acid, (+)-camphoric acid, (-)-camphoric acid, (*S*)-(+)-2-phenylpropionic acid, (*R*)-(+)-2-phenylpropionic acid, D-(-)-mandelic acid, L-(+)-mandelic acid, D-tartaric acid, L-tartaric acid, or a mixture of two or more thereof.

It will be appreciated that the compounds that are useful according to the present invention may contain asymmetric centres. These asymmetric centres may be, independently, in *R* or *S* configuration. It will be clear to a person skilled in the art that certain compounds that are useful according to the invention may also exhibit geometrical isomerism. It should be understood that the present invention includes individual geometrical isomers and stereoisomers and mixtures thereof, including racemic mixtures, of compounds of the formula (I) above. Isomers of this type can be separated from mixtures thereof by application or adaptation of known processes, for example chromatography techniques or recrystallisation techniques, or they are prepared separately from suitable isomers of their intermediates.

For the purposes of this text, it is understood that the tautomeric forms are included in the mention of a given group, for example thio/mercapto or oxo/hydroxy.

The enantiomers of the compounds according to the invention and the process for separating them are especially described in patent application WO 2004/089917.

The present patent application also concerns the polymorphic forms of the compounds, as obtained according to patent application WO 2004/089917, for instance the A1 polymorphic form of the salt (+)-2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine hydrochloride.

The present invention also relates to the other polymorphic forms of the compounds, such as the H1 polymorphic form of the salt (+)-2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine hydrochloride, which can be prepared as follows:

- 5 Approximately 3 g of the A1 form of Example 18 are dissolved in 50 ml of 1 mol/l HCl at room temperature. The clear solution obtained is left to evaporate at room temperature, in an open beaker, until a solid residue crystallises.

The characterisation is performed by:

▪ FT-IR spectroscopy:

- 10 - Brüker Vector 22
 - 2 cm⁻¹ spectral resolution
 - 32 scans
 - KBR discs (analogous to method A AA21505)
 - To evaluate the intensity of the IR bands, the IR spectra were normal-
15 ised by vectorisation in the spectral range 4000-400 cm⁻¹ as an absorption spectrum.

Preadjustment was performed:

- s: A > 0.05
 - m: 0.01 < A < 0.05
20 - w: A < 0.01.

▪ FT-Raman spectroscopy:

- Brüker RFS-100
 - excitation: 1064 nm
 - spectral resolution: 1 cm⁻¹
25 - 1000 mW
 - 1000 scans
 - focalised
 - aluminium crucible (analogous to method RA AA21505)
 - To evaluate the intensity of the Raman bands, Raman spectra were
30 normalised by vectorisation in the spectral range 3600-200 cm⁻¹. Pre-
adjustment was performed:
 - s: A > 0.05
 - m: 0.01 < A < 0.05

- w: A < 0.01

▪ Powder x-ray diffraction (XRD)

- diffractometer D5000 (Brüker AXS)
- radiation CuK α 1 at 1.5406 Å (U=30 kV, A=40 mA)
- Transmission mode
- Detector in sensitive position
- Primary monochromator
- Angle range: 3-65°2 θ
- Stage width: 0.05 °2 θ
- Measuring time/stage: 1.4 s
- The XRD machine is set at 2 θ \pm 0.1°.

Results

A1 form:

15 XRD:

No.	d[Å]	2 θ	I/I ₀
1	5.98	14.8	85
2	5.26	16.8	83
3	4.35	20.4	30
4	3.57	24.9	100
5	3.50	25.4	53
6	3.36	26.5	96
7	3.31	26.9	52
8	3.04	29.3	57
9	2.90	30.8	30
10	2.74	32.7	35

FT-IR bands (in cm⁻¹):

3384 +/- 1.5 (m), 3199 +/- 1.5 (m), 3163 +/- 1.5 (m), 3107 +/- 1.5 (m), 2993 +/-
 20 1.5 (m), 2983 +/- 1.5 (m), 1652 +/- 1.5 (s), 1606 +/- 1.5 (s), 1576 +/- 1.5 (s),
 1557 +/- 1.5 (s), 1505 +/- 1.5 (s), 1449 +/- 1.5 (m), 1427 +/- 1.5 (m), 1405 +/-
 1.5 (m), 1383 +/- 1.5 (m), 1348 +/- 1.5 (m), 1306 +/- 1.5 (m), 1263 +/- 1.5 (w),
 1235 +/- 1.5 (w), 1185 +/- 1.5 (w), 1096 +/- 1.5 (w), 1068 +/- 1.5 (w), 980 +/- 1.5

(w), 946 +/- 1.5 (w), 868 +/- 1.5 (w), 761 +/- 1.5 (w), 687 +/- 1.5 (m), 655 +/- 1.5 (m), 558 +/- 1.5 (w), 521 +/- 1.5 (w), 478 +/- 1.5 (w)

FT-Raman bands (in cm^{-1}):

5 3217 +/- 1.5 (w), 2994 +/- 1.5 (m), 2983 +/- 1.5 (m), 2936 +/- 1.5 (s), 2883 +/- 1.5 (m), 1645 +/- 1.5 (w), 1602 +/- 1.5 (m), 1554 +/- 1.5 (m), 1453 +/- 1.5 (m), 1428 +/- 1.5 (m), 1349 +/- 1.5 (w), 1308 +/- 1.5 (w), 979 +/- 1.5 (m), 866 +/- 1.5 (w), 761 +/- 1.5 (w), 686 +/- 1.5 (s), 583 +/- 1.5 (m), 555 +/- 1.5 (s), 525 +/- 1.5 (m), 479 +/- 1.5 (m), 410 +/- 1.5 (m), 401 +/- 1.5 (m), 307 +/- 1.5 (m)

10 H1 form

XRD:

No.	d[Å]	2 θ	I/I ₀
1	8.03	11.0	69
2	7.27	12.2	25
3	6.11	14.5	24
4	4.01	22.1	86
5	3.64	24.5	100
6	3.26	27.3	51
7	3.08	29.0	29
8	3.04	29.4	34
9	2.82	31.7	61
10	2.66	33.6	26

FT-IR bands (in cm^{-1}):

3386 +/- 1.5 (m), 3080 +/- 3 (m), 1706 +/- 1.5 (s), 1691 +/- 1.5 (s), 1634 +/- 1.5 (m), 1513 +/- 1.5 (m), 1445 +/- 1.5 (w), 1241 +/- 1.5 (w), 1079 +/- 1.5 (w), 989 +/- 1.5 (w), 940 +/- 1.5 (w), 861 +/- 1.5 (w), 823 +/- 1.5 (w), 675 +/- 1.5 (w), 603 +/- 1.5 (w), 573 +/- 1.5 (w), 549 +/- 1.5 (w), 527 +/- 1.5 (w)

The compounds of the formula (I) above also include the prodrugs of these compounds.

The term "prodrugs" means compounds which, when administered to the patient, are chemically and/or biologically converted in the live body into compounds of the formula (I).

In the present description, the terms used have, unless otherwise indicated, the following meanings:

- the term "(C1-C20)alkyl" denotes a linear or branched alkyl radical containing from 1 to 20 carbon atoms. Among the C1-C20 alkyl radicals that may especially be mentioned, in a non-limiting manner, are methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, octyl, decyl, dodecyl, hexadecyl and octadecyl radicals;

- the term "(C1-C20)alkenyl" denotes a linear or branched hydrocarbon-based radical containing one or more unsaturations in double bond form. As alkylene radicals containing from 1 to 20 carbon atoms, mention may be made, in a non-limiting manner, of ethenyl, prop-2-enyl, but-2-enyl, but-3-enyl, pent-2-enyl, pent-3-enyl and pent-4-enyl radicals;

- the term "(C1-C20)alkynyl" denotes a linear or branched hydrocarbon-based radical containing one or more unsaturations in triple bond form. As alkylene radicals containing from 1 to 20 carbon atoms, mention may be made, in a non-limiting manner, of ethynyl, prop-2-ynyl, but-2-ynyl, but-3-ynyl, pent-2-ynyl, pent-3-ynyl and pent-4-ynyl radicals;

- the term "alkoxy" refers to the term "alkyl-oxy";

- the term "halogen" refers, in a non-limiting manner, to fluorine, chlorine or bromine;

- the term "(C6-C14)aryl" refers to an aromatic group containing from 6 to 14 carbon atoms with at least one of the rings having a system of conjugated pi electrons, and including biaryls, which may be optionally substituted. Mention will be made in particular of biphenyl, phenyl, naphthyl, anthryl and phenanthryl radicals;

- the term "hetero(C6-C14)aryl" refers to a 6-14-membered aromatic heterocycle containing 1-4 heteroatoms, the other atoms being carbon atoms. Among the heteroatoms, mention will be made in particular of oxygen, sulfur and nitrogen. Among the heteroaryl radicals, mention will be made more par-

ticularly of furyl, thienyl, pyridyl, pyrrolyl, pyrimidyl, pyrazinyl, oxazolyl, oxadiazolyl, isoxazolyl, quinolyl and thiazolyl radicals;

- the term "(C3-C8)cycloalkyl" refers to a saturated hydrocarbon-based ring and contains monocyclic, bicyclic and polycyclic radicals containing from 3
5 to 8 carbon atoms. Mention will be made, in a non-limiting manner, of cyclopropyl and cyclobutyl radicals;

- the term "(C6-C14)aryl(C1-C20)alkyl" refers to the corresponding -alkylaryl groups. Mention will be made in particular of benzyl and phenethyl groups.

10 The medicaments according to the invention may be in a form for local use, advantageously of the oil, cream, mousse, liniment, lotion, pomade, liquid, gel, milk, powder or spray type.

The forms may comprise a one-phase vehicle, consisting of a neutral hydroxypropylcellulose gel or of a charged gel formed from sodium carboxymethylcellulose. Creams, forms with a two-phase vehicle, comprising a hydrophilic phase dispersed in a lipophilic phase, can also be prepared.

Advantageously, the medicament contains from 0.02% to 2% by weight of the triazine derivative of the general formula (I) or of a pharmaceutically acceptable salt thereof and a suitable excipient. These excipients can be chosen
20 from compounds that show good compatibility with these active principles. They are, for example, water-soluble polymers of natural polymer type, such as polysaccharides (xanthan gum, locust bean gum, pectin, etc.) or polypeptides, cellulose derivatives, such as methylcellulose, hydroxypropylcellulose or hydroxypropylmethylcellulose, or alternatively synthetic polymers, poloxamers, carbomers, PVA or PVP.

Finally, it is within the capacity of any person skilled in the art to add to these medicaments various excipients of co-solvent type, for instance ethanol, glycerol, benzyl alcohol, humectants (glycerol), diffusion aids (Transcutol, urea), or antibacterial preserving agents (methyl, butyl or propyl p-hydroxybenzoate at
30 0.15%, taken alone or as mutual combination).

In one particular embodiment of the invention, the triazine derivatives or pharmaceutically acceptable salts thereof are combined with at least one other active principle. This active principle may be, for example, of the type, such as

an antibacterial, antifungal or antiviral agent, making it possible to accelerate the cicatrisation of damage and infected tissue, simultaneously or in combination with the treatment of the underlying infection.

This active principle may also consist of another agent for improving cicatrisation, such as epithelial growth factor, fibroblast growth factor, platelet-derived growth factor, etc.

The present invention also relates to a cicatrising pharmaceutical composition and/or a pharmaceutical composition having an angiogenic effect, for topical use, comprising, as active principle, a therapeutically effective amount of triazine derivatives of the general formula (I) or of pharmaceutically acceptable salts thereof, advantageously (+)-2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine hydrochloride, in a suitable vehicle. The vehicle may be an excipient as described above. Advantageously, the composition contains from 0.02% to 2% by weight of the triazine derivative or of the pharmaceutically acceptable salt thereof.

Advantageously, the composition according to the present invention is in a pharmaceutical form for local use, advantageously of the type, such as a pomade, liquid, gel, milk, powder, spray, oil, cream, mousse, liniment or lotion.

In one preferred embodiment, the composition according to the invention contains at least one other active principle, as discussed previously.

The triazine derivatives of the general formula (I) and the pharmaceutically acceptable salts thereof, in particular (+)-2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine hydrochloride, thus improve the cicatrisation of wounds or lesions of any type, including surgical incisions, thermal or chemical burns or burns caused by irradiation, abrasions, lacerations, amputations, ischaemic or decubitus ulcers, lesions or ulcers of the mouth, stomach or intestine or corneal lesions, and in particular those caused by a surgical operation performed on weakened or elderly individuals, treated by radiotherapy or chemotherapy, or diabetics. This is likewise the case for all dermatoses observed in the case of patients whose cutaneous circulation is deficient (erythematous lesions or vascularites) and all wounds observed in the case of diabetics. The pharmaceutical compositions and medicaments according to the invention appear to be beneficial even for the treatment of post-thrombotic tissue necroses, for example.

11756-73

19

The frequency of application of the pharmaceutical formulation can vary within wide ranges (one to several times a day) as a function of the nature and severity of the wound, and also the age and weight of the individual.

The examples below of compositions according to the invention are given as non-limiting illustrations.

EXAMPLES

The amounts are expressed on a weight basis.

Formulation example 1: unit formula for 100 grams of gel

(+)-2-Amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine hydrochloride: 2 grams

NaOH pellets: 0.01 gram

Hydroxyethylcellulose (NatrosolTM 250 HX): 2 grams

Monopotassium phosphate: 0.65 gram

Purified water: qs 100 grams

Formulation example 2: unit formula for 150 grams of emulsion:

(+)-2-Amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine hydrochloride: 1 gram.

33% Hydrocerine pomade (H/L) (hydrophilic phase dispersed in a lipophilic phase). (Fatty excipient from Roc®, containing petroleum jelly, liquid paraffin, triglycerides, polyoxyethylene ethers and ceresin): 98.80 grams

Methyl p-hydroxybenzoate: 0.2 gram

Purified water: qs 150 grams

Biological results

On diabetic rats (STZ), the induction of injuries and their quantification are determined on the backs of predetermined groups of rats.

The animals are anaesthetised, using a matrix painted with a tattoo dye. An incision 1.5×1.5 cm deep, including the panniculus carnosus muscle, is

made in the middle of the back. The injuries accompanied by size markers are analysed with a digital camera at the time of injury and every three days up to the point of closure of the incision. The salt (+)-2-amino-3,6-dihydro-4-dimethyl-amino-6-methyl-1,3,5-triazine hydrochloride is studied after topical application at
5 various concentrations and after several days of treatment.

USE OF TRIAZINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT HAVING A CICATRISING OR ANGIOGENIC EFFECT

Field of the invention

5 The present invention relates in particular to the use of triazine derivatives or pharmaceutically acceptable salts thereof for the manufacture of a medicament having a cicatrising and/or angiogenic effect.

Technical background

10 The cicatrisation of wounds or related damage on different types of tissue generally depends on the proliferation of new epithelial, endothelial and connective tissue. It thus involves a series of co-ordinated cellular and molecular events. It may be retarded or modified by metabolic disruptions that accompany certain protracted diseases, such as venous insufficiency, arteritis, diabetes and
15 even certain therapies.

 Angiogenesis, the formation of new blood vessels from the pre-existing vascular network, is essential for the growth of any tissue. It takes place, inter alia, in damaged tissue during its cicatrisation. It is well known that disruption of angiogenesis is associated with the development of many diseases involving a
20 deregulation of vascularisation. Many bibliographical data show, for example, a close link between the appearance of ulcers and the inhibition of angiogenesis in the case of diabetics. Furthermore, it is well documented that the endothelial cells constituting the blood vessels of the peripheral circulation are one of the many targets of damage induced by hyperglycaemia (diabetic microangio-
25 pathy). The pharmaceutical market currently offers many topical preparations recommended for the cicatrisation of wounds. In point of fact, their action results from the complementary nature of the various products of which they are composed and which gives them, to a certain extent, their cicatrising property. They protect wounds from the surrounding medium by means of an antiseptic dress-
30 ing. They stimulate the development of vascularisation and regulate epidermisation. These topical forms consist mainly of a lipid mixture (lanolin, petroleum jelly, glycerol, etc.) to which are added acids (salicylic acid, benzoic acid or malic acid), minerals (zinc oxide or titanium oxide) or halides (starch iodide).

Certain preparations also contain collagen, fibrinogen, serum enzymatic proteolysate (supply of amino acids) or alternatively vitamins (vitamin A) or hormones (4-chlorotestosterone acetate).

A pomade also exists (Madecasin® tulgras from Laboratoires Syntex),
 5 the cicatrising action of which is provided by the addition of a mixture of three triterpenes extracted from roots of the plant *Centella asiatica* (TCEA).

These compounds exert their property by stimulating the biosynthesis of collagen and of glycosaminoglycans. However, these extracts may also give rise to contact allergies in patients.


10 It is known that one of the complications of diabetes lies in the appearance of skin complaints, such as ulcers (or even ulcerous necrotic angiodermatitis) or perforating dermatitis, which conventional medicaments used for the treatment of diabetes do not manage to control or treat.

15 Description of the invention

The hypoglycaemiant properties of and preparations derived from triazines of the formula (I) have previously been described in FR 2 804 113 and WO 01/ 55122.

Unexpectedly, the applicant has now demonstrated that these com-
 20 pounds, or pharmaceutically acceptable salts thereof, also have a cicatrising and/or angiogenic effect.

More particularly, the invention relates to the use of derivatives of the general formula (I) below:



(I)

25

in which:

R1, R2, R3 and R4 are independently chosen from the following groups:

-H,

30 -(C1-C20)alkyl optionally substituted by halogen, (C1-C5)alkyl, (C1-C5)-alkoxy or (C3-C8)cycloalkyl,

-(C2-C20)alkenyl optionally substituted by halogen, (C1-C5)alkyl or (C1-C5)alkoxy

-(C2-C20)alkynyl optionally substituted by halogen, (C1-C5)alkyl or (C1-C5)alkoxy

5 -(C3-C8)cycloalkyl optionally substituted by (C1-C5)alkyl or (C1-C5)-alkoxy

 -hetero(C3-C8)cycloalkyl bearing one or more heteroatoms chosen from N, O and S and optionally substituted by (C1-C5)alkyl or (C1-C5)alkoxy

 -(C6-C14)aryl(C1-C20)alkyl optionally substituted by amino, hydroxyl,
10 thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkyl-
amino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl,
carboxyl, carboxymethyl or carboxyethyl,

 - (C6-C14)aryl optionally substituted by amino, hydroxyl, thio, halogen,
15 (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)-
aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxy-
methyl or carboxyethyl,

 -(C1-C13)heteroaryl bearing one or more heteroatoms chosen from N, O
and S and optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)-
alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy,
20 (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or
carboxyethyl,

 R1 and R2, on the one hand, and R3 and R4, on the other hand, possibly
forming with the nitrogen atom an n-membered ring (n between 3 and 8) op-
tionally containing one or more heteroatoms chosen from N, O and S and pos-
sibly being substituted by one or more of the following groups: amino, hydroxyl,
25 thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkyl-
amino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl,
carboxyl, carboxymethyl or carboxyethyl,

 R5 and R6 are independently chosen from the following groups:

30 -H,

 -(C1-C20)alkyl optionally substituted by amino, hydroxyl, thio, halogen,
(C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)-

aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,

-(C2-C20)alkenyl optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,

-(C2-C20)alkynyl optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,

-(C3-C8)cycloalkyl optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,

-hetero(C3-C8)cycloalkyl bearing one or more heteroatoms chosen from N, O and S and optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,

-(C6-C14)aryl optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,

-(C1-C13)heteroaryl bearing one or more heteroatoms chosen from N, O and S and optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,

-(C6-C14)aryl(C1-C5)alkyl optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl,

11756-73


5

- R5 and R6 possibly forming with the carbon atom to which they are attached an m-membered ring (m between 3 and 8) optionally containing one or more heteroatoms chosen from N, O and S and possibly being substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, tri-fluoromethyl, carboxyl, carboxymethyl or carboxyethyl, or possibly forming with the carbon atom with the carbon atom a C10-C30 polycyclic residue optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)-alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxethyl, R5 and R6 together also possibly representing the group=O or =S, the nitrogen atom of a heterocycloalkyl or heteroaryl group possibly being substituted by a (C1-C5)alkyl, (C3-C8)cycloalkyl, (C6-C14)aryl, (C6-C14)aryl, (C6-C14)aryl(C1-C5)alkyl or (C1-C6)acyl group,

and also the racemic forms, tautomers, enantiomers, diastereoisomers, epimers and mixtures thereof, and the pharmaceutically acceptable salts thereof,

for the preparation of a medicament having a cicatrising and/or angiogenic effect.

According to one aspect, the present invention relates to an use of a triazine derivative compound of the general formula (I) below:



in which: R1, R2, R3 and R4 are independently chosen from the following groups:

20 -H,

5a

- (C1-C20)alkyl optionally substituted by halogen, (C1-C5)alkyl, (C1-C5)-alkoxy or (C3-C8)cycloalkyl,


R5 and R6 are independently chosen from the following groups:

- H,
 - (C1-C20)alkyl optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)-aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxy-methyl or carboxyethyl,

or the racemic forms, tautomers, enantiomers, diastereoisomers, epimers and polymorphs, or any mixtures thereof, or a pharmaceutically acceptable salt thereof,

in the preparation of a medicament for promoting cicatrisation.

According to one aspect, the present invention relates to an use of a triazine derivative compound of the general formula (I) below:



in which: R1, R2, R3 and R4 are independently chosen from the following groups:


-H,
 -(C1-C20)alkyl optionally substituted by halogen, (C1-C5)alkyl, (C1-C5)-alkoxy or (C3-C8)cycloalkyl,

R5 and R6 are independently chosen from the following groups:

-H,

5b

-(C1-C20)alkyl optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl, or the racemic forms, tautomers, enantiomers, diastereoisomers, epimers and polymorphs, or any mixtures thereof, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament having an use of triazine derivatives of the general formula (I) below:



in which:

R1, R2, R3 and R4 are independently chosen from the following groups:

- H,

- (C1-C20)alkyl optionally substituted by halogen, (C1-C5)alkyl, (C1-C5)-alkoxy or (C3-C8)cycloalkyl,

R5 and R6 are independently chosen from the following groups:

- H,

- (C1-C20)alkyl optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)-aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxy-methyl or carboxyethyl,

or the racemic forms, tautomers, enantiomers, diastereoisomers, epimers and polymorphs, or any mixtures thereof, or a pharmaceutically acceptable salt thereof,

5c

in the preparation of a medicament for promoting cicatrisation.

The term "m-membered ring formed by R5 and R6" in particular means a saturated ring, such as a cyclohexyl piperidyl or tetrahydropyranyl group.

The term "polycyclic group formed by R5 and R6" means an optionally substituted carbon –based polycyclic group and in particular as steroid residue.

One particular group of compounds of the formula (I) is that in which R5 is hydrogen.

Another particular group of compounds of the formula (I) is that in which R5 and R6 form with the carbon atom to which they are attached an m-membered ring (m between 3 and 8) optionally containing one or more heteroatoms chosen from N, O and S and possibly being substituted by one or more of the following groups: (C1-C5)alkyl, amino, hydroxyl, (C1-C5) alkylamino, alkoxy-(C1-C5), (C1-C5)alkylthio, (C6-C14)aryl, (C6-C14)aryl(C1-C5)alkoxy,

or form with the carbon atom a C10-C30 polycyclic residue optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy,

(C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)-alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl.

Another particular group of compounds of the formula (I) is that in which R5 and R6 are independently chosen from the following groups:



- 5 -(C1-C20)alkyl groups optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl.











10 Preferably, R1, R2, R3 and R4 are independently chosen from H and (C1-C20)alkyl groups optionally substituted by halogen, (C1-C5)alkyl, (C1-C5)alkoxy or (C3-C8)cycloalkyl; more preferably, R1=R2=H and R3=R4=(C1-C20)alkyl optionally substituted by halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C3-C8)cycloalkyl or vice versa.











15 Preferably, R5 and R6 are independently chosen from H and (C1-C20)alkyl groups optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)-aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxy-methyl or carboxyethyl; more preferably, R5=H and R6=(C1-C20)alkyl optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-
20 C5)alkylthio, (C1-C5)alkylamino, (C6-C14)aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxymethyl or carboxyethyl or vice versa.










A more particular group of compounds of the formula (I) is that in which R1 and R2 are a methyl group and R3 and R4 represent a hydrogen.











Compounds of the formula (I) that may especially be mentioned include:





	Formula	Salt
1		HCl
2		HCl

3		
4		HCl
5		Methane-sulfonate
6		
7		HCl
8		HCl
9		HCl
10		HCl
11		HCl
12		HCl

13		
14		Fumarate
15		HCl
16		HCl
17		HCl
18		HCl
19		HCl
20		Carbonate
21		Carbonate
22		HCl

23		HCl
24		HCl
25		HCl
26		HCl
27		HCl
28		HCl
29		Carbonate
30		Carbonate
31		HCl

32		Carbonate
33		HCl
34		para-Toluene-sulfonate
35		HCl
36		para-Toluene-sulfonate
37		para-Toluene-sulfonate
38		HCl
39		HCl
40		HCl
41		para-Toluene-sulfonate

42		HCl
43		HCl
44		HCl
45		para-Toluene-sulfonate

and more preferably the compound of Example 18.

According to yet another preferred embodiment, the invention relates more particularly to the use of compounds chosen from:

- 5 • 2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine hydrochloride
- (+)-2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine hydrochloride
- (-)-2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine
- 10 hydrochloride.

The compounds of the invention of the formula (I) as defined above, containing a sufficiently basic function, or both, may include the corresponding pharmaceutically acceptable salts of organic or mineral acids.

For the purposes of the present invention, the term "corresponding
15 pharmaceutically acceptable salts of organic or mineral acids" means any salt prepared from any non-toxic pharmaceutically acceptable organic or inorganic acid. Such acids include acetic acid, benzenesulfonic acid, benzoic acid, citric acid, carbonic acid, ethanesulfonic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, lactic acid, mandelic acid, malic acid,
20 maleic acid, methanesulfonic acid, mucic acid, nitric acid, panto-

11756-73

12

thenic acid, phosphoric acid, succinic acid, tartaric acid and para-toluenesulfonic acid. Hydrochloric acid is advantageously used.

The invention also relates to the chiral salts of the compounds of the formula (I) used for the separation of the racemates.

By way of example, the following chiral acids are used: (+)-D-di-O-benzoyltartaric acid, (-)-L-di-O-benzoyltartaric acid, (-)-L-di-O,O'-p-toluyll-L-tartaric acid, (+)-D-di-O,O'-p-toluyll-L-tartaric acid, (*R*)-(+)-malic acid, (*S*)-(-)-malic acid, (+)-camphanic acid, (-)-camphanic acid, *R*-(-)-1,1'-binaphthalen-2,2'-diylhydrogenophosphonic acid, (+)-camphoric acid, (-)-camphoric acid, (*S*)-(+)-2-phenylpropionic acid, (*R*)-(+)-2-phenylpropionic acid, D-(-)-mandelic acid, L-(+)-mandelic acid, D-tartaric acid, L-tartaric acid, or a mixture of two or more thereof.

It will be appreciated that the compounds that are useful according to the present invention may contain asymmetric centres. These asymmetric centres may be, independently, in *R* or *S* configuration. It will be clear to a person skilled in the art that certain compounds that are useful according to the invention may also exhibit geometrical isomerism. It should be understood that the present invention includes individual geometrical isomers and stereoisomers and mixtures thereof, including racemic mixtures, of compounds of the formula (I) above. Isomers of this type can be separated from mixtures thereof by application or adaptation of known processes, for example chromatography techniques or recrystallisation techniques, or they are prepared separately from suitable isomers of their intermediates.

For the purposes of this text, it is understood that the tautomeric forms are included in the mention of a given group, for example thio/mercapto or oxo/hydroxy.

The enantiomers of the compounds according to the invention and the process for separating them are especially described in patent application WO 2004/089917.

The present patent application also concerns the polymorphic forms of the compounds, as obtained according to patent application WO 2004/089917, for instance the A1 polymorphic form of the salt (+)-2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine hydrochloride.

The present invention also relates to the other polymorphic forms of the compounds, such as the H1 polymorphic form of the salt (+)-2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine hydrochloride, which can be prepared as follows:

- 5 Approximately 3 g of the A1 form of Example 18 are dissolved in 50 ml of 1 mol/l HCl at room temperature. The clear solution obtained is left to evaporate at room temperature, in an open beaker, until a solid residue crystallises.

The characterisation is performed by:

▪ FT-IR spectroscopy:

- 10 - Brüker Vector 22
 - 2 cm⁻¹ spectral resolution
 - 32 scans
 - KBR discs (analogous to method A AA21505)
 - To evaluate the intensity of the IR bands, the IR spectra were normal-
15 ised by vectorisation in the spectral range 4000-400 cm⁻¹ as an absorption spectrum.

Preadjustment was performed:

- s: A > 0.05
 - m: 0.01 < A < 0.05
20 - w: A < 0.01.

▪ FT-Raman spectroscopy:

- Brüker RFS-100
 - excitation: 1064 nm
 - spectral resolution: 1 cm⁻¹
25 - 1000 mW
 - 1000 scans
 - focalised
 - aluminium crucible (analogous to method RA AA21505)
 - To evaluate the intensity of the Raman bands, Raman spectra were
30 normalised by vectorisation in the spectral range 3600-200 cm⁻¹. Pre-
adjustment was performed:
 - s: A > 0.05
 - m: 0.01 < A < 0.05

- w: A < 0.01

▪ Powder x-ray diffraction (XRD)

- diffractometer D5000 (Brüker AXS)
- radiation CuK α 1 at 1.5406 Å (U=30 kV, A=40 mA)
- Transmission mode
- Detector in sensitive position
- Primary monochromator
- Angle range: 3-65°2 θ
- Stage width: 0.05 °2 θ
- Measuring time/stage: 1.4 s
- The XRD machine is set at 2 θ \pm 0.1°.

Results

A1 form:

15 XRD:

No.	d[Å]	2 θ	I/I ₀
1	5.98	14.8	85
2	5.26	16.8	83
3	4.35	20.4	30
4	3.57	24.9	100
5	3.50	25.4	53
6	3.36	26.5	96
7	3.31	26.9	52
8	3.04	29.3	57
9	2.90	30.8	30
10	2.74	32.7	35

FT-IR bands (in cm⁻¹):

3384 +/- 1.5 (m), 3199 +/- 1.5 (m), 3163 +/- 1.5 (m), 3107 +/- 1.5 (m), 2993 +/-
 20 1.5 (m), 2983 +/- 1.5 (m), 1652 +/- 1.5 (s), 1606 +/- 1.5 (s), 1576 +/- 1.5 (s),
 1557 +/- 1.5 (s), 1505 +/- 1.5 (s), 1449 +/- 1.5 (m), 1427 +/- 1.5 (m), 1405 +/-
 1.5 (m), 1383 +/- 1.5 (m), 1348 +/- 1.5 (m), 1306 +/- 1.5 (m), 1263 +/- 1.5 (w),
 1235 +/- 1.5 (w), 1185 +/- 1.5 (w), 1096 +/- 1.5 (w), 1068 +/- 1.5 (w), 980 +/- 1.5

(w), 946 +/- 1.5 (w), 868 +/- 1.5 (w), 761 +/- 1.5 (w), 687 +/- 1.5 (m), 655 +/- 1.5 (m), 558 +/- 1.5 (w), 521 +/- 1.5 (w), 478 +/- 1.5 (w)

FT-Raman bands (in cm^{-1}):

5 3217 +/- 1.5 (w), 2994 +/- 1.5 (m), 2983 +/- 1.5 (m), 2936 +/- 1.5 (s), 2883 +/- 1.5 (m), 1645 +/- 1.5 (w), 1602 +/- 1.5 (m), 1554 +/- 1.5 (m), 1453 +/- 1.5 (m), 1428 +/- 1.5 (m), 1349 +/- 1.5 (w), 1308 +/- 1.5 (w), 979 +/- 1.5 (m), 866 +/- 1.5 (w), 761 +/- 1.5 (w), 686 +/- 1.5 (s), 583 +/- 1.5 (m), 555 +/- 1.5 (s), 525 +/- 1.5 (m), 479 +/- 1.5 (m), 410 +/- 1.5 (m), 401 +/- 1.5 (m), 307 +/- 1.5 (m)

10 H1 form

XRD:

No.	d[Å]	2 θ	I/I ₀
1	8.03	11.0	69
2	7.27	12.2	25
3	6.11	14.5	24
4	4.01	22.1	86
5	3.64	24.5	100
6	3.26	27.3	51
7	3.08	29.0	29
8	3.04	29.4	34
9	2.82	31.7	61
10	2.66	33.6	26

FT-IR bands (in cm^{-1}):

3386 +/- 1.5 (m), 3080 +/- 3 (m), 1706 +/- 1.5 (s), 1691 +/- 1.5 (s), 1634 +/- 1.5 (m), 1513 +/- 1.5 (m), 1445 +/- 1.5 (w), 1241 +/- 1.5 (w), 1079 +/- 1.5 (w), 989 +/- 1.5 (w), 940 +/- 1.5 (w), 861 +/- 1.5 (w), 823 +/- 1.5 (w), 675 +/- 1.5 (w), 603 +/- 1.5 (w), 573 +/- 1.5 (w), 549 +/- 1.5 (w), 527 +/- 1.5 (w)

The compounds of the formula (I) above also include the prodrugs of these compounds.

The term "prodrugs" means compounds which, when administered to the patient, are chemically and/or biologically converted in the live body into compounds of the formula (I).

In the present description, the terms used have, unless otherwise indicated, the following meanings:

- the term "(C1-C20)alkyl" denotes a linear or branched alkyl radical containing from 1 to 20 carbon atoms. Among the C1-C20 alkyl radicals that may especially be mentioned, in a non-limiting manner, are methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, octyl, decyl, dodecyl, hexadecyl and octadecyl radicals;

- the term "(C1-C20)alkenyl" denotes a linear or branched hydrocarbon-based radical containing one or more unsaturations in double bond form. As alkylene radicals containing from 1 to 20 carbon atoms, mention may be made, in a non-limiting manner, of ethenyl, prop-2-enyl, but-2-enyl, but-3-enyl, pent-2-enyl, pent-3-enyl and pent-4-enyl radicals;

- the term "(C1-C20)alkynyl" denotes a linear or branched hydrocarbon-based radical containing one or more unsaturations in triple bond form. As alkylene radicals containing from 1 to 20 carbon atoms, mention may be made, in a non-limiting manner, of ethynyl, prop-2-ynyl, but-2-ynyl, but-3-ynyl, pent-2-ynyl, pent-3-ynyl and pent-4-ynyl radicals;

- the term "alkoxy" refers to the term "alkyl-oxy";

- the term "halogen" refers, in a non-limiting manner, to fluorine, chlorine or bromine;

- the term "(C6-C14)aryl" refers to an aromatic group containing from 6 to 14 carbon atoms with at least one of the rings having a system of conjugated pi electrons, and including biaryls, which may be optionally substituted. Mention will be made in particular of biphenyl, phenyl, naphthyl, anthryl and phenanthryl radicals;

- the term "hetero(C6-C14)aryl" refers to a 6-14-membered aromatic heterocycle containing 1-4 heteroatoms, the other atoms being carbon atoms. Among the heteroatoms, mention will be made in particular of oxygen, sulfur and nitrogen. Among the heteroaryl radicals, mention will be made more par-

ticularly of furyl, thienyl, pyridyl, pyrrolyl, pyrimidyl, pyrazinyl, oxazolyl, oxadiazolyl, isoxazolyl, quinolyl and thiazolyl radicals;

- the term "(C3-C8)cycloalkyl" refers to a saturated hydrocarbon-based ring and contains monocyclic, bicyclic and polycyclic radicals containing from 3
5 to 8 carbon atoms. Mention will be made, in a non-limiting manner, of cyclopropyl and cyclobutyl radicals;

- the term "(C6-C14)aryl(C1-C20)alkyl" refers to the corresponding -alkylaryl groups. Mention will be made in particular of benzyl and phenethyl groups.

10 The medicaments according to the invention may be in a form for local use, advantageously of the oil, cream, mousse, liniment, lotion, pomade, liquid, gel, milk, powder or spray type.

The forms may comprise a one-phase vehicle, consisting of a neutral hydroxypropylcellulose gel or of a charged gel formed from sodium carboxymethylcellulose. Creams, forms with a two-phase vehicle, comprising a hydrophilic phase dispersed in a lipophilic phase, can also be prepared.

Advantageously, the medicament contains from 0.02% to 2% by weight of the triazine derivative of the general formula (I) or of a pharmaceutically acceptable salt thereof and a suitable excipient. These excipients can be chosen
20 from compounds that show good compatibility with these active principles. They are, for example, water-soluble polymers of natural polymer type, such as polysaccharides (xanthan gum, locust bean gum, pectin, etc.) or polypeptides, cellulose derivatives, such as methylcellulose, hydroxypropylcellulose or hydroxypropylmethylcellulose, or alternatively synthetic polymers, poloxamers, carbomers, PVA or PVP.

Finally, it is within the capacity of any person skilled in the art to add to these medicaments various excipients of co-solvent type, for instance ethanol, glycerol, benzyl alcohol, humectants (glycerol), diffusion aids (Transcutol, urea), or antibacterial preserving agents (methyl, butyl or propyl p-hydroxybenzoate at
30 0.15%, taken alone or as mutual combination).

In one particular embodiment of the invention, the triazine derivatives or pharmaceutically acceptable salts thereof are combined with at least one other active principle. This active principle may be, for example, of the type, such as

an antibacterial, antifungal or antiviral agent, making it possible to accelerate the cicatrisation of damage and infected tissue, simultaneously or in combination with the treatment of the underlying infection.

This active principle may also consist of another agent for improving cicatrisation, such as epithelial growth factor, fibroblast growth factor, platelet-derived growth factor, etc.

The present invention also relates to a cicatrising pharmaceutical composition and/or a pharmaceutical composition having an angiogenic effect, for topical use, comprising, as active principle, a therapeutically effective amount of triazine derivatives of the general formula (I) or of pharmaceutically acceptable salts thereof, advantageously (+)-2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine hydrochloride, in a suitable vehicle. The vehicle may be an excipient as described above. Advantageously, the composition contains from 0.02% to 2% by weight of the triazine derivative or of the pharmaceutically acceptable salt thereof.

Advantageously, the composition according to the present invention is in a pharmaceutical form for local use, advantageously of the type, such as a pomade, liquid, gel, milk, powder, spray, oil, cream, mousse, liniment or lotion.

In one preferred embodiment, the composition according to the invention contains at least one other active principle, as discussed previously.

The triazine derivatives of the general formula (I) and the pharmaceutically acceptable salts thereof, in particular (+)-2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine hydrochloride, thus improve the cicatrisation of wounds or lesions of any type, including surgical incisions, thermal or chemical burns or burns caused by irradiation, abrasions, lacerations, amputations, ischaemic or decubitus ulcers, lesions or ulcers of the mouth, stomach or intestine or corneal lesions, and in particular those caused by a surgical operation performed on weakened or elderly individuals, treated by radiotherapy or chemotherapy, or diabetics. This is likewise the case for all dermatoses observed in the case of patients whose cutaneous circulation is deficient (erythematous lesions or vascularites) and all wounds observed in the case of diabetics. The pharmaceutical compositions and medicaments according to the invention appear to be beneficial even for the treatment of post-thrombotic tissue necroses, for example.

11756-73

19

The frequency of application of the pharmaceutical formulation can vary within wide ranges (one to several times a day) as a function of the nature and severity of the wound, and also the age and weight of the individual.

The examples below of compositions according to the invention are given as non-limiting illustrations.

EXAMPLES

The amounts are expressed on a weight basis.

Formulation example 1: unit formula for 100 grams of gel

(+)-2-Amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine hydrochloride: 2 grams

NaOH pellets: 0.01 gram

Hydroxyethylcellulose (NatrosolTM 250 HX): 2 grams

Monopotassium phosphate: 0.65 gram

Purified water: qs 100 grams

Formulation example 2: unit formula for 150 grams of emulsion:

(+)-2-Amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine hydrochloride: 1 gram.

33% Hydrocerine pomade (H/L) (hydrophilic phase dispersed in a lipophilic phase). (Fatty excipient from Roc®, containing petroleum jelly, liquid paraffin, triglycerides, polyoxyethylene ethers and ceresin): 98.80 grams

Methyl p-hydroxybenzoate: 0.2 gram

Purified water: qs 150 grams

Biological results


On diabetic rats (STZ), the induction of injuries and their quantification are determined on the backs of predetermined groups of rats.

The animals are anaesthetised, using a matrix painted with a tattoo dye. An incision 1.5×1.5 cm deep, including the panniculus carnosus muscle, is

made in the middle of the back. The injuries accompanied by size markers are analysed with a digital camera at the time of injury and every three days up to the point of closure of the incision. The salt (+)-2-amino-3,6-dihydro-4-dimethyl-amino-6-methyl-1,3,5-triazine hydrochloride is studied after topical application at
5 various concentrations and after several days of treatment.

CLAIMS

1. Use of triazine derivatives of the general formula (I) below:



in which:

5 R1, R2, R3 and R4 are independently chosen from the following groups:

- H,

- (C1-C20)alkyl optionally substituted by halogen, (C1-C5)alkyl, (C1-C5)-alkoxy or (C3-C8)cycloalkyl,

R5 and R6 are independently chosen from the following groups:

10 - H,

- (C1-C20)alkyl optionally substituted by amino, hydroxyl, thio, halogen, (C1-C5)alkyl, (C1-C5)alkoxy, (C1-C5)alkylthio, (C1-C5)alkylamino, (C6-C14)-aryloxy, (C6-C14)aryl(C1-C5)alkoxy, cyano, trifluoromethyl, carboxyl, carboxy-methyl or carboxyethyl,

15 or the racemic forms, tautomers, enantiomers, diastereoisomers, epimers and polymorphs, or any mixtures thereof, or a pharmaceutically acceptable salt thereof,

in the preparation of a medicament for promoting cicatrisation, wherein the medicament is in a pharmaceutical form for local use.

2. Use according to claim 1, in which R5 is hydrogen.

3. Use according to claim 1 or 2, wherein R1 and R2 are a methyl group and R3
20 and R4 represent hydrogen.

4. Use according to any one of claims 1 to 3, in the manufacture of a medicament for promoting cicatrisation of wounds of diabetics.

5. Use according to any one of claims 1 to 4, wherein the compound of the formula (I) is 2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine or a pharmaceutically acceptable salt thereof.

6. Use according to any one of claims 1 to 5, wherein the compound of the formula (I) is (-)-2-amino-3,6-dihydro-4-dimethyl-amino-6-methyl-1,3,5-triazine or a pharmaceutically acceptable salt thereof.

7. Use according to any one of claims 1 to 5, wherein the compound of the formula (I) is (+)-2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine or a pharmaceutically acceptable salt thereof.

8. Use according to any one of claims 1 to 7, wherein the compound of the formula (I) is in the form of a hydrochloride.

9. Use according to any one of claims 1 to 8, wherein the medicament contains from 0.02% to 2% by weight of the compound of the formula (I) or the pharmaceutically acceptable salt thereof and a pharmaceutically suitable excipient.

10. Use according to any one of claims 1 to 9, wherein the compound of the formula (I) or the pharmaceutically acceptable salt thereof is combined with one or more other antibiotics, antifungal or antiviral active principles.

11. Cicatrising pharmaceutical composition for topical use comprising, as active principle, a therapeutically effective amount of a compound of the general formula (I) as defined in any one of claims 1 to 8 or the pharmaceutically acceptable salt thereof and a pharmaceutically suitable excipient.

12. Composition according to claim 11, comprising one or more other active principle(s).

13. Composition according to claim 11 or 12, comprising from 0.02% to 2% by weight of the compound of the formula (I) or of the pharmaceutically acceptable salt thereof.

